RESPONSE RATE OF SOFOSBUVIR BASED ANTIVIRAL THERAPY AMONG PATIENTS INFECTED WITH HEPATITIS C VIRUS GENOTYPE 3A

Main Article Content

Ijaz Ali
Amina Gul
Atika Noorul Sahar
Shahid Niaz ``Khan
Sadeequr Rahman
Imtiaz Ali Khan
Johar Jamil

Abstract

Objective: To evaluate the efficacy of dual therapy of Sofosbuvir and Ribavirin among treatment-naive and non-responders
of Interferon based antiviral regimens against HCV genotype 3a infected patients.
Material & Methods: A longitudinal study was conducted on 100 HCV genotype 3a infected patients from December
2016 to September 2017. Patients were initially divided into two groups including Group-A (n=50/100) as treatment
naive, and Group-B (n=50/100) including non-responders. All patients received Sofosbuvir and RBV for 24weeks. HCV
genotype was determined using Type-specific nested PCR based genotyping assay. Viral RNA was detected using
qualitative or real-time PCR.
Results: After 4 weeks of treatment, HCV RNA was undetectable in 100 of Group A patients, while Group B patients
achieved 92% RVR. SVR12 was 96% in treatment naïve Group A patients, while Group B patients achieved an SVR12 of
90%. There were no significant differences in the SVR12 rates between the two treatment groups (Pearson Chi-Square
test, p-value >0.05). The association of RVR and SVR12 was found statistically significant (Pearson Chi-Square test,
p- value<0.05).
Conclusion: Sofosbuvir and RBV is highly effective among the treatment-naive and previously treated chronic HCV
genotype 3a infected patients.

Article Details

How to Cite
AliI., GulA., SaharA., ``KhanS., RahmanS., KhanI., & JamilJ. (2019). RESPONSE RATE OF SOFOSBUVIR BASED ANTIVIRAL THERAPY AMONG PATIENTS INFECTED WITH HEPATITIS C VIRUS GENOTYPE 3A. Journal Of Medical Sciences, 27(4), 295-301. Retrieved from https://jmedsci.com/index.php/Jmedsci/article/view/785
Section
Articles